Gilead Sciences (GILD) to Resume Trading at 4:25PM ET Following Strong Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/21/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
About 9,000 Hep C patients have been cured with Sovaldi to date - Gilead (GILD)
July 23, 2014 4:48 PM EDTGilead Sciences (NASDAQ: GILD) said about 9,000 Hep C patients have been cured with Sovaldi to date
... MoreGilead Sciences, Inc. (GILD) Tops Q2 EPS by 63c; Boosts FY14 Revenue Outlook
July 23, 2014 4:07 PM EDTGilead Sciences, Inc. (NASDAQ: GILD) reported Q2 EPS of $2.36, $0.63 better than the analyst estimate of $1.73. Revenue for the quarter came in at $6.53 billion versus the consensus estimate of $5.68 billion.
During the second quarter, Gilead continued to make significant progress led by strong Sovaldi sales. Since Decembers launch, Sovaldi has been prescribed for more than 80,000 patients in the U.S. and Europe, underscoring the medical communitys recognition of the benefits of this product, said John C. Martin, PhD, Gileads Chairman and Chief Executive Officer. We look forward to making Sovaldi available in additional... More
